Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Pharma Industry News Halozyme Therapeutics to acquire specialty pharma company Antares Pharma for $960m Halozyme Therapeutics, a California-based publicly-listed biotech company, has agreed to acquire New Jersey-based specialty pharma company Antares Pharma… bySrinathApril 16, 2022